I think most hospital procurement departments get wound care purchasing fundamentally backwards. We focus on unit price, we run competitive bids to squeeze the last dime out of suppliers, and we treat dressings like they are interchangeable commodities.
That mindset is costing us more money, not less. And it is quietly damaging the clinical reputation of our facilities.
I say this as someone who has overseen surgical supply procurement for a 350-bed acute care hospital for the last 6 years. I manage a wound care budget of roughly $180,000 annually (not counting surgical), and I have audited every single purchase order dating back to 2019. I have chased down every hidden fee, every inventory write-off, and every nurse complaint logged about a dressing that didn't stick.
The False Economy of the Low Bid
When I first took over procurement in 2020, I did what any reasonable cost controller would do: I compared 8 vendors on price. Vendor A quoted $0.45 per sheet for a basic foam dressing. Vendor B (our incumbent) was at $0.85. I almost switched to Vendor A immediately.
Then I looked closer.
That 'budget' dressing had a 14% clinical failure rate in our pilot trial (documented in our internal wound care log for Q1 2021). It required a secondary dressing to stay in place. It caused skin stripping in 3 out of 40 patients. Our wound care nurses literally begged me not to switch. (This was back in 2021. I still have the email thread.)
The hidden costs were brutal: nursing time for re-applications, extra inventory for secondary dressings, longer healing times (which meant more days in the hospital for some patients), and the intangible but very real cost of eroded clinician trust in the supply chain.
The Mölnlycke Cost Model
This is where Mölnlycke became a permanent fixture in our formulary. At first glance, a Mölnlycke Melgisorb Plus calcium alginate dressing costs more per unit than a generic competitor. I've seen our purchasing team wince at the line item.
But I've also seen the data. Over 6 years, I've tracked every order for Melgisorb Plus against alternative alginates. The total cost of care (labor, inventory waste, secondary products) for the Mölnlycke product was 17% lower per patient episode. That is a real number from our system.
Why? Because the quality of the dressing reduces the number of required changes (Mölnlycke's Safetac® technology is not just marketing fluff—it genuinely minimizes pain and skin damage during removal). Fewer changes mean less nursing labor. Less labor means lower total cost. It's not complicated math, but it requires looking past the unit price.
"I can only speak to our hospital's experience. If your facility has a different patient mix or a different staffing model, the math might be different. But for us, the clinical quality of the dressing directly drives the bottom line."
Quality Perception Is Not Soft—It's a Financial Asset
Here is the argument that usually gets me in trouble with the pure cost-cutters: the quality of your wound care products directly impacts how patients and surgeons perceive your entire hospital.
In 2023, I did a internal survey connecting patient satisfaction scores (HCAHPS) with the ward where they received post-surgical wound care. The surgical ward using Mölnlycke dressings (Melgisorb Plus for exudating wounds, Mepilex for pressure areas) consistently scored 11 points higher on "communication about healing" and 8 points higher on overall satisfaction versus the ward using alternative products.
Yes, correlation is not causation. But when surgeons notice that a wound is healing cleanly, without maceration, and with minimal pain at dressing change (which, honest, is rare with cheaper alternatives), they notice the brand. They start asking 'what dressings are we using in OR?' That word-of-mouth has a real value in maintaining our hospital's reputation for surgical excellence.
The question isn't 'Is Mölnlycke worth it?' The question is 'Can you afford the consequences of not using high-quality products?' If a dressing fails and a wound gets infected, the cost of that complication (potentially thousands of dollars in extended stay and antibiotics) dwarfs the $0.40 per dressing 'savings.'
Addressing the 'But What About Holter Monitors and CT Scanners?' Objection
Someone is going to read this and say: "This is procurement for a wound clinic. A Holter monitor costs $500. A CT scanner is a million-dollar capital asset. You can't compare a $3 dressing to that."
Fair point. I don't directly manage capital equipment. Those are different beasts with completely different procurement cycles (and totally different politics. (Lucky me.)
But the principle is the same. Buying a cheap Holter monitor that gives inaccurate readings because it's poorly designed? That generates more work for the cardiology department, more re-tests, more patient dissatisfaction. The 'savings' on the monitor evaporates in the first false alarm.
Similarly, a CT scanner that is cheaper to buy but has higher downtime or requires proprietary service contracts is not a bargain. Total Cost of Ownership (TCO) applies at every scale. Wound care is just a much higher-volume, lower-cost-per-unit environment where many procurement managers get lazy.
My Bottom Line
I have mixed feelings about my own job. Part of me is supposed to squeeze every penny. Another part of me knows that the cheapest option is almost never the most cost-effective option in healthcare.
For a wound care department that values clinical outcomes, nursing efficiency, and patient perception (and yes, I think you should value those things): invest in products like Mölnlycke Melgisorb Plus or Mepilex. The upfront sticker price hurts. The long-term P&L looks significantly better. Our data proves it.
This approach worked for us, but our situation is a mid-size hospital with a dedicated wound care team and predictable ordering patterns. If you are a small clinic managing cash flow day-by-day, the calculus is different. You may need to prioritize upfront liquidity over long-term savings. I get it. But do not pretend the long-term savings aren't real.
This pricing and TCO data was accurate as of Q4 2024. Market conditions change, especially with raw material costs. Always verify current pricing against your own usage data.
